Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 World Health Organization. Global Health Estimates: deaths by cause, age, sex and country, 2000–2012. WHO, Geneva, Switzerland (2014).
  Google Scholar
• 2 World Health Organization. Projections of mortality and causes of death, 2015 and 2030. www.who.int/healthinfo/global_burden_disease/projections/en/.
  Google Scholar
• 3 Suntsov YuI, Bolotskaya LL, Maslova OV, Kazakov IV. Epidemiology of diabetes mellitus and prognosis of its prevalence in the Russian Federation. Saharnyj Diabet. 14(1), 15–18 (2011).
  Google Scholar
• 4 Ringborg A, Cropet C, Jönsson B, Gagliardino JJ, Ramachandran A, Lindgren P. Resource use associated with Type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int. J. Clin. Pract. 63(7), 997–1007 (2009).
  Medline CASGoogle Scholar
• 5 Chan JC, Gagliardino JJ, Baik SH et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 32(2), 227–233 (2009).
  MedlineGoogle Scholar
• 6 American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE). AACE/ACE Comprehensive Type 2 diabetes management algorithm 2016. Endocr. Pract. 22, 84–113 (2016).
  MedlineGoogle Scholar
• 7 Zhou K, Pedersen HK, Dawed AY, Pearson ER. Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nat. Rev. Endocrinol. 12(6), 337–346 (2016). •• The most recent and complete review on antidiabetic drug pharmacogenetics.
  Medline CASGoogle Scholar
• 8 Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 12(8), 1161–1191 (2011).
  CASGoogle Scholar
• 9 Kirchheiner J, Brockmoller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 71(4), 286–296 (2002).
  Medline CASGoogle Scholar
• 10 Hu GX, Pan PP, Wang ZS et al. In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population. Drug Metab. Dispos. 43(4), 561–569 (2015).
  Medline CASGoogle Scholar
• 11 Dai DP, Wang SH, Geng PW, Hu GX, Cai JP. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride. Basic Clin. Pharmacol. Toxicol. 114(4), 305–310 (2014).
  Medline CASGoogle Scholar
• 12 Niinuma Y, Saito T, Takahashi M et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 14(2), 107–114 (2014).
  Medline CASGoogle Scholar
• 13 Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12(2), 101–109 (2002).
  Medline CASGoogle Scholar
• 14 Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with Type 2 diabetes. Diabetes Res. Clin. Pract. 72(2), 148–154 (2006).
  Medline CASGoogle Scholar
• 15 Tan B, Zhang YF, Chen XY et al. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur. J. Clin. Pharmacol. 66(2), 145–151 (2010).
  Medline CASGoogle Scholar
• 16 Surendiran A, Pradhan SC, Agrawal A et al. Influence of CYP2C9 gene polymorphismus on response to glybenclamide in Type 2 diabetes mellitus patients. Eur. J. Clin. Pharmacol. 67(8), 797–801 (2011).
  Medline CASGoogle Scholar
• 17 Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 73(3), 326–332 (2002).
  Google Scholar
• 18 Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes. Clin. Pharmacol. Ther. 72(5), 562–571 (2002).
  Medline CASGoogle Scholar
• 19 Becker M, Visser L, Trienekens P, Hofman A, van Schaik R, Stricker B. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type II diabetes mellitus. Clin. Pharmacol. Ther. 83(2), 288–292 (2008).
  Medline CASGoogle Scholar
• 20 Zhou K, Donnelly L, Burch L et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in Type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Therap. 87(1), 52–56 (2010). • The large population-based study including a sample of 1073 people for CYP2C9 testing.
  Medline CASGoogle Scholar
• 21 Edridge CL, Dunkley AJ, Bodicoat DH et al. Prevalence and incidence of hypoglycaemia in 532,542 people with Type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS ONE 10(6), e0126427 (2015).
  MedlineGoogle Scholar
• 22 Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10(11), 1781–1787 (2009). • Shows correlation between *3 allele and hypoglycemia frequency in patients.
  CASGoogle Scholar
• 23 Ragia G, Tavridou A, Elens L, van Schaik RH, Manolopoulos VG. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 Type 2 diabetic patients treated with sulfonylureas. Exp. Clin. Endocrinol. Diabetes 122(1), 60–63 (2014).
  Medline CASGoogle Scholar
• 24 Holstein A, Plaschke A, Ptak M et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 60(1), 103–106 (2005).
  Medline CASGoogle Scholar
• 25 Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur. J. Clin. Pharmacol. 67(5), 471–476 (2011).
  Medline CASGoogle Scholar
• 26 Céspedes-Garro C, Fricke-Galindo I, Naranjo ME et al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin. Drug Metab. Toxicol. 11(12), 1893–1905 (2015). •• Unites data on 75 CYP2C9 polymorphism studies in 16 ethnicities.
  MedlineGoogle Scholar
• 27 Dorado P, Beltrán LJ, Machín E et al. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender. Pharmacogenomics 13(15), 1711–1717 (2012).
  CASGoogle Scholar
• 28 Varshney E, Saha N, Tandon M, Shrivastava V, Ali S. Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital region. Eur. J. Drug Metab. Pharmacokinet. 38(4), 275–282 (2013).
  Medline CASGoogle Scholar
• 29 Shao H, Ren XM, Liu NF et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J. Clin. Pharm. Ther. 35(3), 351–360 (2010).
  Medline CASGoogle Scholar
• 30 Ren Q, Han X, Zhang S, Cai X, Ji L. Combined influence of genetic variants and gene–gene interaction on sulfonylurea efficacy in Type 2 diabetic patients. Exp. Clin. Endocrinol. Diabetes 124(3), 157–162 (2016).
  Medline CASGoogle Scholar
• 31 Shao H, Lu J, Xu YT, Zhan Y, Chen GM, Zhang HJ. Metabolic interaction potential between clopidogrel and sulfonylurea antidiabetic agents: effects on clopidogrel bioactivation. Pharmacology 97(1–2), 18–24 (2016).
  Medline CASGoogle Scholar
• 32 Harmsze AM, Van Werkum JW, Moral F et al. Sulfonylureas and on-clopidogrel platelet reactivity in Type 2 diabetes mellitus patients. Platelets 22(2), 98–102 (2011).
  Medline CASGoogle Scholar
• 33 Chen SZ, Pan PP, Wang SH et al. In vitro and in vivo drug–drug interaction of losartan and glimepiride in rats and its possible mechanism. Pharmacology 95(3–4), 133–138 (2015).
  Medline CASGoogle Scholar
• 34 Chen SZ, Pan PP, Shen LB et al. Drug–drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. Int. J. Clin. Pharmacol. Ther. 52(9), 732–738 (2014).
  Medline CASGoogle Scholar
• 35 Petrov VI, Rogova NV, Ledyaev YaM, Ozerov AA, Serdyukova DM. Farmacokinetic testing of CYP2C9 activity in Type 2 diabetes mellitus patients as a way to reduce frequency of adverse effects. Biomedicine 3(1), 113–115 (2010).
  Google Scholar
• 36 Petrov VI, Rogova NV, Ledyaev YaM, Serdyukova DM. Influence of long-term therapy with sulfonylurea derivatives on the capacity of the hepatic CYP2C9 enzyme system of drug biotransformation in diabetic type II patients in the city of Volgograd. Vestnik VolGMU 2(34), 14–18 (2010). • Describes enzyme depletion during a long-term treatment.
  Google Scholar
• 37 Lagishetty CV, Deng J, Lesko LJ, Rogers H, Pacanowski M, Schmidt S. How informative are drug-drug interactions of gene-drug interactions? J. Clin. Pharmacol. doi:10.1002/jcph.743 (2016) (Epub ahead of print). • Describes the impact of CYP2C19 of CYP2C9 activity.
  Google Scholar
• 38 Koren S, Koren R, Bar-Chaim A et al. Any polymorphisms of CYP2C9 affects the biochemical profile of diabetic patients receiving glibenclamide. Clin. Med. Biochem. Open Access 1, 102 (2015).
  Google Scholar
• 39 Type of metabolism depending on CYP2C9 genotype – PharmGKB guideline. www.pharmgkb.org/guideline/PA166122806.
  Google Scholar
• 40 Human Cytochrome P450 (CYP) Allele Nomenclature for CYP2C9. www.cypalleles.ki.se/cyp2c9.htm.
  Google Scholar
• 41 Sirotkina OV, Ulitina AS, Taraskina AE et al. CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy. Rossijskij kardiologicheskij zhurnal 6(50), 47–50 (2004).
  Google Scholar
• 42 Hardy–Weinberg Equilibrium Calculator. www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-3-alleles.html.
  Google Scholar
• 43 Tsarukyan AA, Baturin VA. Genetic polymorphism of the isoenzymes of cytochrome CYP2C9 in the ethnic groups from the Stavropol region. Kubanskij nauchnyj medicinskij vestnik 133(4), 181–183 (2012).
  Google Scholar
• 44 Korchagina RP, Osipova LP, Vavilova NA, Voronina EN, Filipenko ML. Genetic polymorphism of drug-metabolizing cytochrome P450 2C9 in indigenous people populations of Northern Siberia. Sibirskij nauchnyj medicinskij zhurnal 31(6), 39–46 (2011).
  Google Scholar
• 45 Dmitrenko DV, Shnayder NA, Nikolaeva TE et al. Ethnic aspects of carriage of CYP2C9 gene polymorphism in children and adolescents with epilepsy in eastern and northeastern Siberia. Modern Prob. Sci. Educ. 62(6), 1–9 (2015).
  Google Scholar
• 46 Guzeva OV, Imyanitov EN. The clinical significance of the study of polymorphism of detoxification P450 CYP2C9 and CYP2C19 in children with epilepsy. Jepilepsija i paroksizmal'nye sostojanija 5(3), 17–23 (2013).
  Google Scholar
• 47 Tsvetovskaya GA, Chikova ED, Koh NV, Lifshits GI, Morozov VV, Novikova YaV. Modern methods of laboratory diagnostics in prevention of recurrent thrombosis. Fundamental'nye issledovanija 10(2), 353–355 (2012).
  Google Scholar
• 48 Gra O, Mityaeva O, Berdichevets I et al. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians. Genet. Test. Mol. Biomarkers 14(3), 329–342 (2010).
  Medline CASGoogle Scholar
• 49 National Structure of Russia. www.statdata.ru/nacionalnyj-sostav-rossii.
  Google Scholar
• 50 Emigration data for the Russians. www.migrationpolicycentre.eu/docs/migration_profiles/Russia.pdf.
  Google Scholar
• 51 Covvey JR, Lewis DA. Glimepiride-induced hypoglycemia with ciprofloxacin, metronidazole, and acute kidney injury. Hosp. Pharm. 45(12), 934–938 (2010).
  CASGoogle Scholar
• 52 Kim YM, Yoo SH, Kang RY et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am. J. Health. Syst. Pharm. 64(2), 166–175 (2007).
  MedlineGoogle Scholar